Correction to: Acta Pharmacol Sin https://doi.org/10.1038/s41401-020-00501-7, published online 25 August 2020
The authors apologize that they did not declare competing interest in the original article.
Competing interests: PFR, PhD, is a stakeholder in Maitland Pharma, a US company that in-licenses and manufactures therapeutic products from snake venom, but not cobrotoxin. PFR also holds several issued patents and patents pending in relation to the therapeutic use of snake venoms. The other authors declare that they have no competing interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lin, F., Reid, P.F. & Qin, Zh. Author Correction: Cobrotoxin could be an effective therapeutic for COVID-19. Acta Pharmacol Sin 41, 1621 (2020). https://doi.org/10.1038/s41401-020-00533-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41401-020-00533-z
